Digestible investing insights
  • Do Your Research
  • YouTube
  • Podcast
  • Investor Hubs
    • Starter Investors Hub
    • Dividend Seekers Hub
    • The Risk Hub
    • COVID-19 Investing Hub
  • Sign Up
  • Boot Camp

Get Detailed Fundamental Research

Join 80k+ investors on our free newsletter and Stock Card platform who learn the tactics and receive tools to make fundamental investment decisions confidently and efficiently.
Join Us
We only ask your name and email address.

Jumia (JMIA): Buy the dip?

6/29/2021

 

KEY POINTS

  • The Consumer Confidence Report boosted the market into the green today.
  • Cerevel Therapeutics (CERE) jumps 136% after announcing positive trial results for their breakthrough schizophrenia treatment.
  • The so-called “Amazon of Africa,” Jumia Technologies (JMIA) is struggling with its operations, giving investors a chance to buy the dip. 

OVERALL MARKET

The Consumer Confidence Report boosted the market into the green today, but only slightly.
Picture
All three indices finished Tuesday in the green, but only barely. 

This may be due in part to the new Consumer Confidence Report released today. This report gives us an idea of how consumers see the state of the economy. The report shows growing labor market optimism and a purchase-oriented attitude going forward.

The S&P was split roughly 50/50 between gaining and losing stocks today, with not much market breadth as you would expect for ending 4 days in a row positive. This is indicative of investor interest surrounding more specific stocks, than the market as a whole.

Get the Daily Market Recap Report

Did you know you can get your Daily Market recap report on YouTube, listen to it on our Podcast, or get it in your inbox?

Watch it,
Listen to it, 
Or, read it.
 

Sign up for a free Stock Card account to get the report in your mailbox every day.
Give Stock Card A Try!

WHAT'S UP?

Cerevel Therapeutics (CERE) jumps 136% after announcing positive trial results for their breakthrough schizophrenia treatment.
Cerevel Therapeutics Holdings Inc (CERE) was one of the biggest gainers on Stock Card’s winners and losers lists today. Cerevel is a neuroscience research and development company with plans to revolutionize medical treatment for mental diseases. 

Yesterday, it reported positive clinical trial results for the drug CVL-231, which combats schizophrenia. This once-daily medicine has much fewer side effects than other treatments, so it’s not a surprise that the company’s shares shot up 136% today. 

Cerevel has multiple compounds currently going through clinical trials and more in the pipeline, so the stock can keep growing. But, at the same time, it has the risk of crashing if there is bad news from any of the trials.

When it comes to drug development stocks, what matters is whether the company has enough cash available to keep at its trials without running out of money. Also, drug development stocks are typically risky bets with extreme volatility. So if you invest, be ready for high volatility. 

WHAT'S DOWN?

The so-called “Amazon of Africa,” Jumia Technologies (JMIA) is struggling with its operations, giving investors a chance to buy the dip.
For the loser stock of the day, let's talk about the “Amazon of Africa,” as they call this next company. Over the course of last year, Jumia Technologies (JMIA) share price shot up over 398%. Today, we’re taking a look at the stock because of it’s 21% drop this quarter. It’s currently hovering quite lower than its all-time high. Even over a few months, such a high price jump is hard to sustain for any company. This is even more difficult if you struggle to turn a profit, like Jumia. 

Despite being widely used in 11 African countries, the company has high overhead costs, such as upkeeping warehouses. Therefore, Jumia is transitioning its business model. This includes expanding into the third-party and dropshipping market and investing in infrastructure for pick-up locations. May’s earnings report reassured investors that they have a strategy to become profitable.

Moreover, its new FinTech division JumiPay is expected to increase profits and encourage customers to purchase more from within the Jumia ecosystem. 

While this transition may look promising, it puts the company through a rough patch. I worry the company is stretching too thin geographically and across several business units, attempting to expand and evolve so much of its strategy at once. As an example, revenue was down 13% last year partially due to these growing pains. 

Nevertheless, Jumia is on track to be a massive player across the African market. The challenges to scale operations is such a big hurdle that it would be hard for other players to achieve what Jumia has already done. So, my strategy is to bet small and steady when I find the stock beaten down. 

WANT TO RECIEVE THIS DAILY STOCK MARKET RECAP IN YOUR MAILBOX?

Sign up for a free account on Stock Card's website to get the daily market recap reports in your inbox:
Give Stock Card A Try!

Comments are closed.

    RSS Feed

    Join Us!

    Join 80K Stock Card users to get these Weekly Fundamental Researches and access Stock Card platform!
    Join Us
    We only ask your name and email address.

    Archives

    May 2023
    April 2023
    March 2023
    December 2022
    September 2022
    July 2022
    February 2022
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    February 2021
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    January 2020
    October 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017

    Categories

    All
    Battle
    Education
    ETF Investing
    Fundamental Analysis
    How To Invest
    New Podcast Episode
    New Portfolio
    Portfolio Update
    Starter 2020
    Stock Card VIP Pick
    Stock Lists
    The Daily Hype
    Update
    Watchlist Worthy
    Winners And Losers

© 2023 StockCard.io. All Rights Reserved.
​​
Disclaimer: StockCard.io is not, neither operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on StockCard.io and Stock Card Weekly represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The Stock Card team may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall StockCard.io be liable to any subscriber, visitor, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on StockCard.io, or relating to the use of, or inability to use, StockCard.io or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
  • Do Your Research
  • YouTube
  • Podcast
  • Investor Hubs
    • Starter Investors Hub
    • Dividend Seekers Hub
    • The Risk Hub
    • COVID-19 Investing Hub
  • Sign Up
  • Boot Camp